Moderna and Merck's Personalized mRNA Vaccine Hits Phase 3 Endpoints for Melanoma

Moderna and Merck announced on August 19, 2026, that their personalized mRNA cancer vaccine met its primary endpoints in a pivotal Phase 3 clinical trial. The results mark a significant milestone in oncology, demonstrating that a patient-specific vaccine can effectively reduce the return of high-risk melanoma.

The treatment, known as intismeran autogene (V940/mRNA-4157), was tested in the INTerpath-001 trial, which enrolled 1,137 patients with surgically removed cutaneous melanoma. When administered alongside the immunotherapy drug Keytruda (pembrolizumab), the combination significantly improved recurrence-free survival (RFS) and prolonged survival without distant metastasis for patients with stage IIB-IV melanoma. Following these results, the companies intend to engage with regulators for filing submissions and may seek accelerated approval.

The Science of Bespoke Therapy

Unlike traditional cancer vaccines that target proteins common to many patients, this mRNA approach is entirely bespoke. The process begins with a biopsy of the patient's tumor, which is sequenced and compared against their healthy cells. This analysis allows scientists to identify up to 34 unique mutations, or neoantigens, specific to that individual's cancer. The mRNA vaccine then trains the immune system to recognize and attack these specific markers.

This vaccine is paired with Keytruda, an anti-PD-1 therapy. While the vaccine primes the immune system to find the cancer, Keytruda blocks the "don't attack me" signals that cancer cells typically use to evade detection. This dual-action strategy leverages the speed of RNA synthesis to create a highly flexible, patient-specific defense. The efficacy of this approach was signaled in an earlier Phase 2 trial of 157 people, where the combination reduced the risk of recurrence or death by 49% and the risk of spread to distant parts of the body by 59% over five years compared to using Keytruda alone.

Industry Implications

This trial represents the first time a personalized cancer vaccine has produced positive results in a final-stage clinical trial. "For many years, the idea of creating an mRNA treatment designed specifically for an individual patient's cancer was aspirational," said Moderna CEO Stéphane Bancel. "We are now helping turn that vision into a reality."

If approved, the therapy could redefine the standard of care for patients with completely resected high-risk melanoma. Dean Li, M.D., Ph.D., president of Merck Research Laboratories, noted that individualized neoantigen therapies have the potential to fundamentally change how these patients are treated following surgery.

Future Outlook

While the current focus is on melanoma, the success of the INTerpath-001 trial provides a blueprint for treating other solid tumors. Trials are already underway for other cancer types, including lung, kidney, and bladder cancers. The medical community will now watch for the formal regulatory submission and the specific data regarding the long-term durability of the response in the larger Phase 3 cohort.